nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—Mitomycin—urinary bladder cancer	0.117	0.278	CbGbCtD
Mefloquine—BCHE—Cisplatin—urinary bladder cancer	0.0961	0.229	CbGbCtD
Mefloquine—CYP3A4—Thiotepa—urinary bladder cancer	0.053	0.126	CbGbCtD
Mefloquine—ABCB1—Gemcitabine—urinary bladder cancer	0.0336	0.0801	CbGbCtD
Mefloquine—HBA1—urine—urinary bladder cancer	0.0291	0.202	CbGeAlD
Mefloquine—ABCB1—Cisplatin—urinary bladder cancer	0.0244	0.0582	CbGbCtD
Mefloquine—ABCB1—Etoposide—urinary bladder cancer	0.024	0.0571	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—urinary bladder cancer	0.0164	0.039	CbGbCtD
Mefloquine—ABCB1—Methotrexate—urinary bladder cancer	0.0158	0.0378	CbGbCtD
Mefloquine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0154	0.0367	CbGbCtD
Mefloquine—CYP3A4—Etoposide—urinary bladder cancer	0.0144	0.0342	CbGbCtD
Mefloquine—HBA1—prostate gland—urinary bladder cancer	0.0105	0.0724	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0098	0.0234	CbGbCtD
Mefloquine—HBA2—prostate gland—urinary bladder cancer	0.0096	0.0665	CbGeAlD
Mefloquine—HBA1—renal system—urinary bladder cancer	0.00713	0.0493	CbGeAlD
Mefloquine—HBA2—epithelium—urinary bladder cancer	0.00706	0.0488	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—urinary bladder cancer	0.0068	0.0471	CbGeAlD
Mefloquine—HBA2—renal system—urinary bladder cancer	0.00655	0.0453	CbGeAlD
Mefloquine—HBA1—female reproductive system—urinary bladder cancer	0.00571	0.0395	CbGeAlD
Mefloquine—HBA2—female reproductive system—urinary bladder cancer	0.00524	0.0363	CbGeAlD
Mefloquine—ACHE—prostate gland—urinary bladder cancer	0.00429	0.0297	CbGeAlD
Mefloquine—CYP3A4—urine—urinary bladder cancer	0.00395	0.0274	CbGeAlD
Mefloquine—CYP2D6—urine—urinary bladder cancer	0.00389	0.0269	CbGeAlD
Mefloquine—HBA1—lymph node—urinary bladder cancer	0.00334	0.0231	CbGeAlD
Mefloquine—HBA2—lymph node—urinary bladder cancer	0.00307	0.0212	CbGeAlD
Mefloquine—ADORA1—renal system—urinary bladder cancer	0.00294	0.0204	CbGeAlD
Mefloquine—CYP19A1—prostate gland—urinary bladder cancer	0.00293	0.0203	CbGeAlD
Mefloquine—ADORA1—urethra—urinary bladder cancer	0.00289	0.02	CbGeAlD
Mefloquine—ADORA2A—female reproductive system—urinary bladder cancer	0.00273	0.0189	CbGeAlD
Mefloquine—ADORA1—female reproductive system—urinary bladder cancer	0.00236	0.0163	CbGeAlD
Mefloquine—ADORA1—vagina—urinary bladder cancer	0.00213	0.0147	CbGeAlD
Mefloquine—BCHE—prostate gland—urinary bladder cancer	0.00211	0.0146	CbGeAlD
Mefloquine—BCHE—seminal vesicle—urinary bladder cancer	0.00178	0.0123	CbGeAlD
Mefloquine—CYP19A1—female reproductive system—urinary bladder cancer	0.0016	0.0111	CbGeAlD
Mefloquine—BCHE—smooth muscle tissue—urinary bladder cancer	0.00149	0.0103	CbGeAlD
Mefloquine—ADORA1—lymph node—urinary bladder cancer	0.00138	0.00954	CbGeAlD
Mefloquine—ACHE—lymph node—urinary bladder cancer	0.00137	0.00948	CbGeAlD
Mefloquine—BCHE—female reproductive system—urinary bladder cancer	0.00115	0.00796	CbGeAlD
Mefloquine—BCHE—vagina—urinary bladder cancer	0.00104	0.0072	CbGeAlD
Mefloquine—ABCB1—prostate gland—urinary bladder cancer	0.001	0.00695	CbGeAlD
Mefloquine—CYP3A4—renal system—urinary bladder cancer	0.000968	0.00669	CbGeAlD
Mefloquine—CYP2D6—renal system—urinary bladder cancer	0.000952	0.00659	CbGeAlD
Mefloquine—CYP19A1—lymph node—urinary bladder cancer	0.000935	0.00647	CbGeAlD
Mefloquine—ABCB1—seminal vesicle—urinary bladder cancer	0.00085	0.00588	CbGeAlD
Mefloquine—CYP3A4—female reproductive system—urinary bladder cancer	0.000775	0.00536	CbGeAlD
Mefloquine—CYP2D6—female reproductive system—urinary bladder cancer	0.000763	0.00528	CbGeAlD
Mefloquine—ABCB1—epithelium—urinary bladder cancer	0.000738	0.00511	CbGeAlD
Mefloquine—ABCB1—renal system—urinary bladder cancer	0.000685	0.00474	CbGeAlD
Mefloquine—BCHE—lymph node—urinary bladder cancer	0.000673	0.00466	CbGeAlD
Mefloquine—ABCB1—urethra—urinary bladder cancer	0.000673	0.00466	CbGeAlD
Mefloquine—ABCB1—female reproductive system—urinary bladder cancer	0.000548	0.0038	CbGeAlD
Mefloquine—ABCB1—vagina—urinary bladder cancer	0.000496	0.00343	CbGeAlD
Mefloquine—ABCB1—lymph node—urinary bladder cancer	0.000321	0.00222	CbGeAlD
Mefloquine—Pneumonia—Epirubicin—urinary bladder cancer	0.000251	0.000849	CcSEcCtD
Mefloquine—Rash—Thiotepa—urinary bladder cancer	0.000249	0.000843	CcSEcCtD
Mefloquine—Dermatitis—Thiotepa—urinary bladder cancer	0.000249	0.000843	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000249	0.000842	CcSEcCtD
Mefloquine—Headache—Thiotepa—urinary bladder cancer	0.000247	0.000838	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000247	0.000837	CcSEcCtD
Mefloquine—Decreased appetite—Etoposide—urinary bladder cancer	0.000247	0.000835	CcSEcCtD
Mefloquine—Renal failure—Epirubicin—urinary bladder cancer	0.000245	0.00083	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000245	0.00083	CcSEcCtD
Mefloquine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000245	0.000829	CcSEcCtD
Mefloquine—Fatigue—Etoposide—urinary bladder cancer	0.000245	0.000828	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000244	0.000828	CcSEcCtD
Mefloquine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000241	0.000815	CcSEcCtD
Mefloquine—Sweating—Epirubicin—urinary bladder cancer	0.000239	0.00081	CcSEcCtD
Mefloquine—Asthenia—Gemcitabine—urinary bladder cancer	0.000238	0.000807	CcSEcCtD
Mefloquine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000236	0.000799	CcSEcCtD
Mefloquine—Pruritus—Gemcitabine—urinary bladder cancer	0.000235	0.000796	CcSEcCtD
Mefloquine—Nausea—Thiotepa—urinary bladder cancer	0.000235	0.000795	CcSEcCtD
Mefloquine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000234	0.000792	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000233	0.000788	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—urinary bladder cancer	0.000232	0.000786	CcSEcCtD
Mefloquine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000232	0.000786	CcSEcCtD
Mefloquine—Pruritus—Fluorouracil—urinary bladder cancer	0.000231	0.000783	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—urinary bladder cancer	0.000231	0.000781	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000229	0.000775	CcSEcCtD
Mefloquine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000228	0.000773	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—urinary bladder cancer	0.000228	0.000772	CcSEcCtD
Mefloquine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000227	0.00077	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—urinary bladder cancer	0.000227	0.000768	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000226	0.000766	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000226	0.000766	CcSEcCtD
Mefloquine—Urticaria—Etoposide—urinary bladder cancer	0.000225	0.000763	CcSEcCtD
Mefloquine—Abdominal pain—Etoposide—urinary bladder cancer	0.000224	0.00076	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—urinary bladder cancer	0.000224	0.00076	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—urinary bladder cancer	0.000224	0.000757	CcSEcCtD
Mefloquine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000224	0.000757	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—urinary bladder cancer	0.000223	0.000755	CcSEcCtD
Mefloquine—Asthenia—Cisplatin—urinary bladder cancer	0.000222	0.000753	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000222	0.000752	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—urinary bladder cancer	0.000221	0.000749	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00022	0.000745	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000218	0.000739	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—urinary bladder cancer	0.000217	0.000735	CcSEcCtD
Mefloquine—Dizziness—Fluorouracil—urinary bladder cancer	0.000216	0.000732	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—urinary bladder cancer	0.000216	0.000731	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000216	0.00073	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000215	0.000729	CcSEcCtD
Mefloquine—Chills—Methotrexate—urinary bladder cancer	0.000215	0.000727	CcSEcCtD
Mefloquine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000212	0.000718	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000212	0.000717	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—urinary bladder cancer	0.000211	0.000716	CcSEcCtD
Mefloquine—Vomiting—Gemcitabine—urinary bladder cancer	0.000211	0.000716	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000211	0.000714	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—urinary bladder cancer	0.00021	0.00071	CcSEcCtD
Mefloquine—Rash—Gemcitabine—urinary bladder cancer	0.00021	0.00071	CcSEcCtD
Mefloquine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000209	0.000709	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—urinary bladder cancer	0.000209	0.000709	CcSEcCtD
Mefloquine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000209	0.000708	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—urinary bladder cancer	0.000209	0.000707	CcSEcCtD
Mefloquine—Erythema—Methotrexate—urinary bladder cancer	0.000208	0.000705	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—urinary bladder cancer	0.000208	0.000705	CcSEcCtD
Mefloquine—Headache—Gemcitabine—urinary bladder cancer	0.000208	0.000705	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000208	0.000704	CcSEcCtD
Mefloquine—Flushing—Epirubicin—urinary bladder cancer	0.000208	0.000704	CcSEcCtD
Mefloquine—Vomiting—Fluorouracil—urinary bladder cancer	0.000208	0.000703	CcSEcCtD
Mefloquine—Rash—Fluorouracil—urinary bladder cancer	0.000206	0.000698	CcSEcCtD
Mefloquine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000206	0.000697	CcSEcCtD
Mefloquine—Headache—Fluorouracil—urinary bladder cancer	0.000205	0.000693	CcSEcCtD
Mefloquine—Asthenia—Etoposide—urinary bladder cancer	0.000204	0.000689	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000204	0.000689	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—urinary bladder cancer	0.000203	0.000688	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000202	0.000683	CcSEcCtD
Mefloquine—Chills—Epirubicin—urinary bladder cancer	0.000201	0.00068	CcSEcCtD
Mefloquine—Pruritus—Etoposide—urinary bladder cancer	0.000201	0.00068	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—urinary bladder cancer	0.0002	0.000676	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—urinary bladder cancer	0.000198	0.00067	CcSEcCtD
Mefloquine—Nausea—Gemcitabine—urinary bladder cancer	0.000197	0.000668	CcSEcCtD
Mefloquine—Vomiting—Cisplatin—urinary bladder cancer	0.000197	0.000667	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—urinary bladder cancer	0.000196	0.000665	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—urinary bladder cancer	0.000196	0.000664	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000196	0.000663	CcSEcCtD
Mefloquine—Rash—Cisplatin—urinary bladder cancer	0.000195	0.000661	CcSEcCtD
Mefloquine—Dermatitis—Cisplatin—urinary bladder cancer	0.000195	0.000661	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—urinary bladder cancer	0.000195	0.00066	CcSEcCtD
Mefloquine—Erythema—Epirubicin—urinary bladder cancer	0.000195	0.00066	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—urinary bladder cancer	0.000194	0.000657	CcSEcCtD
Mefloquine—Nausea—Fluorouracil—urinary bladder cancer	0.000194	0.000657	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000194	0.000656	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000193	0.000654	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000193	0.000654	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—urinary bladder cancer	0.000192	0.000651	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000192	0.000651	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000188	0.000636	CcSEcCtD
Mefloquine—Malaise—Methotrexate—urinary bladder cancer	0.000188	0.000636	CcSEcCtD
Mefloquine—Dizziness—Etoposide—urinary bladder cancer	0.000188	0.000635	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000187	0.000635	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—urinary bladder cancer	0.000187	0.000634	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000187	0.000632	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—urinary bladder cancer	0.000186	0.000631	CcSEcCtD
Mefloquine—Chills—Doxorubicin—urinary bladder cancer	0.000186	0.000629	CcSEcCtD
Mefloquine—Nausea—Cisplatin—urinary bladder cancer	0.000184	0.000623	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—urinary bladder cancer	0.000184	0.000622	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—urinary bladder cancer	0.000183	0.00062	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000181	0.000615	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000181	0.000612	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—urinary bladder cancer	0.00018	0.000611	CcSEcCtD
Mefloquine—Vomiting—Etoposide—urinary bladder cancer	0.00018	0.000611	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—urinary bladder cancer	0.00018	0.000611	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—urinary bladder cancer	0.00018	0.000611	CcSEcCtD
Mefloquine—Agitation—Epirubicin—urinary bladder cancer	0.000179	0.000607	CcSEcCtD
Mefloquine—Rash—Etoposide—urinary bladder cancer	0.000179	0.000606	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—urinary bladder cancer	0.000179	0.000605	CcSEcCtD
Mefloquine—Headache—Etoposide—urinary bladder cancer	0.000178	0.000602	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—urinary bladder cancer	0.000177	0.0006	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—urinary bladder cancer	0.000177	0.0006	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—urinary bladder cancer	0.000177	0.0006	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000176	0.000596	CcSEcCtD
Mefloquine—Malaise—Epirubicin—urinary bladder cancer	0.000176	0.000595	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—urinary bladder cancer	0.000175	0.000593	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—urinary bladder cancer	0.000175	0.000593	CcSEcCtD
Mefloquine—Syncope—Epirubicin—urinary bladder cancer	0.000175	0.000592	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—urinary bladder cancer	0.000174	0.000591	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000173	0.000587	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—urinary bladder cancer	0.000172	0.000583	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—urinary bladder cancer	0.000171	0.00058	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000171	0.00058	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00017	0.000576	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00017	0.000576	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—urinary bladder cancer	0.000169	0.000572	CcSEcCtD
Mefloquine—Nausea—Etoposide—urinary bladder cancer	0.000169	0.000571	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—urinary bladder cancer	0.000168	0.00057	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000167	0.000567	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000167	0.000564	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000166	0.000564	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—urinary bladder cancer	0.000166	0.000562	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—urinary bladder cancer	0.000166	0.000562	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—urinary bladder cancer	0.000166	0.000562	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—urinary bladder cancer	0.000166	0.000561	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—urinary bladder cancer	0.000165	0.00056	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—urinary bladder cancer	0.000165	0.000559	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000165	0.000558	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000164	0.000556	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—urinary bladder cancer	0.000164	0.000555	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—urinary bladder cancer	0.000163	0.000551	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—urinary bladder cancer	0.000162	0.000549	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—urinary bladder cancer	0.000162	0.000548	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000161	0.000547	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—urinary bladder cancer	0.00016	0.000543	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—urinary bladder cancer	0.000159	0.00054	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000159	0.000539	CcSEcCtD
Mefloquine—Oedema—Epirubicin—urinary bladder cancer	0.000159	0.000539	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—urinary bladder cancer	0.000159	0.000538	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000158	0.000537	CcSEcCtD
Mefloquine—Shock—Epirubicin—urinary bladder cancer	0.000156	0.00053	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—urinary bladder cancer	0.000156	0.000529	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000156	0.000528	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000156	0.000527	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—urinary bladder cancer	0.000156	0.000527	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—urinary bladder cancer	0.000155	0.000526	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000155	0.000524	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—urinary bladder cancer	0.000154	0.000523	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000154	0.000521	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—urinary bladder cancer	0.000154	0.000521	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—urinary bladder cancer	0.000154	0.00052	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—urinary bladder cancer	0.000154	0.00052	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000154	0.00052	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—urinary bladder cancer	0.000153	0.000518	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000153	0.000517	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000152	0.000516	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—urinary bladder cancer	0.000152	0.000514	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000152	0.000513	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—urinary bladder cancer	0.000151	0.000512	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00015	0.000507	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—urinary bladder cancer	0.000149	0.000503	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—urinary bladder cancer	0.000148	0.000503	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000148	0.0005	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—urinary bladder cancer	0.000147	0.000498	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000147	0.000498	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000147	0.000497	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—urinary bladder cancer	0.000147	0.000496	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000145	0.000491	CcSEcCtD
Mefloquine—Shock—Doxorubicin—urinary bladder cancer	0.000145	0.00049	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000144	0.000489	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000144	0.000488	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—urinary bladder cancer	0.000144	0.000487	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000144	0.000486	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000143	0.000484	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000143	0.000484	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000142	0.000482	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000142	0.00048	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—urinary bladder cancer	0.000141	0.000479	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00014	0.000474	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—urinary bladder cancer	0.00014	0.000474	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000139	0.000471	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000138	0.000468	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—urinary bladder cancer	0.000138	0.000466	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000137	0.000465	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—urinary bladder cancer	0.000137	0.000464	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—urinary bladder cancer	0.000135	0.000457	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000134	0.000455	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000134	0.000455	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000134	0.000454	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—urinary bladder cancer	0.000133	0.000451	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000132	0.000448	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000131	0.000444	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000131	0.000444	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—urinary bladder cancer	0.000131	0.000443	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00013	0.00044	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00013	0.000439	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000128	0.000433	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000127	0.00043	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—urinary bladder cancer	0.000127	0.00043	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—urinary bladder cancer	0.000126	0.000428	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000126	0.000426	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000126	0.000426	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000125	0.000424	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—urinary bladder cancer	0.000122	0.000413	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000121	0.000411	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00012	0.000408	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—urinary bladder cancer	0.00012	0.000407	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000117	0.000397	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—urinary bladder cancer	0.000117	0.000396	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000116	0.000394	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000116	0.000394	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000116	0.000394	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—urinary bladder cancer	0.000114	0.000386	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—urinary bladder cancer	0.000113	0.000381	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—urinary bladder cancer	0.000112	0.000381	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000109	0.000369	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000108	0.000367	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—urinary bladder cancer	0.000108	0.000366	CcSEcCtD
Mefloquine—Rash—Methotrexate—urinary bladder cancer	0.000107	0.000363	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—urinary bladder cancer	0.000107	0.000363	CcSEcCtD
Mefloquine—Headache—Methotrexate—urinary bladder cancer	0.000106	0.000361	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—urinary bladder cancer	0.000106	0.000358	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—urinary bladder cancer	0.000105	0.000356	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—urinary bladder cancer	0.000104	0.000353	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—urinary bladder cancer	0.000101	0.000342	CcSEcCtD
Mefloquine—Nausea—Methotrexate—urinary bladder cancer	0.000101	0.000342	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000101	0.000341	CcSEcCtD
Mefloquine—Rash—Epirubicin—urinary bladder cancer	0.0001	0.00034	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—urinary bladder cancer	0.0001	0.000339	CcSEcCtD
Mefloquine—Headache—Epirubicin—urinary bladder cancer	9.96e-05	0.000337	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—urinary bladder cancer	9.73e-05	0.00033	CcSEcCtD
Mefloquine—Nausea—Epirubicin—urinary bladder cancer	9.45e-05	0.00032	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—urinary bladder cancer	9.36e-05	0.000317	CcSEcCtD
Mefloquine—Rash—Doxorubicin—urinary bladder cancer	9.28e-05	0.000314	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—urinary bladder cancer	9.27e-05	0.000314	CcSEcCtD
Mefloquine—Headache—Doxorubicin—urinary bladder cancer	9.22e-05	0.000312	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—urinary bladder cancer	8.74e-05	0.000296	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—EGFR—urinary bladder cancer	6.63e-05	0.000471	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.53e-05	0.000464	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CXCL8—urinary bladder cancer	6.42e-05	0.000457	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JAG1—urinary bladder cancer	6.34e-05	0.00045	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NAT2—urinary bladder cancer	6.33e-05	0.00045	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.31e-05	0.000448	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.28e-05	0.000446	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—KRAS—urinary bladder cancer	6.26e-05	0.000445	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.26e-05	0.000445	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NAT2—urinary bladder cancer	6.15e-05	0.000437	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	6.14e-05	0.000437	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.14e-05	0.000436	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—RRM2—urinary bladder cancer	5.95e-05	0.000423	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.81e-05	0.000413	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	5.77e-05	0.00041	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.73e-05	0.000407	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.66e-05	0.000402	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—HPGDS—urinary bladder cancer	5.51e-05	0.000391	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ENO2—urinary bladder cancer	5.51e-05	0.000391	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.48e-05	0.00039	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.48e-05	0.000389	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	5.47e-05	0.000389	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NAT1—urinary bladder cancer	5.47e-05	0.000389	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RBX1—urinary bladder cancer	5.47e-05	0.000388	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—RRM2—urinary bladder cancer	5.46e-05	0.000388	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	5.44e-05	0.000387	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.41e-05	0.000385	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—RHOA—urinary bladder cancer	5.36e-05	0.000381	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTT1—urinary bladder cancer	5.34e-05	0.00038	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.34e-05	0.000379	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—HRAS—urinary bladder cancer	5.32e-05	0.000378	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—RRM2—urinary bladder cancer	5.31e-05	0.000377	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.26e-05	0.000374	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.26e-05	0.000374	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.16e-05	0.000367	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.16e-05	0.000367	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TSC1—urinary bladder cancer	5.14e-05	0.000365	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—S100B—urinary bladder cancer	5.13e-05	0.000365	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ENO2—urinary bladder cancer	5.06e-05	0.00036	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	5.06e-05	0.00036	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.05e-05	0.000359	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.03e-05	0.000358	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.01e-05	0.000356	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—HPGDS—urinary bladder cancer	4.91e-05	0.000349	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ENO2—urinary bladder cancer	4.91e-05	0.000349	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	4.91e-05	0.000349	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JAG1—urinary bladder cancer	4.89e-05	0.000348	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.88e-05	0.000347	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RHOA—urinary bladder cancer	4.86e-05	0.000346	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.83e-05	0.000344	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTT1—urinary bladder cancer	4.77e-05	0.000339	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	4.72e-05	0.000335	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.7e-05	0.000334	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.69e-05	0.000334	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.65e-05	0.000331	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NCOR1—urinary bladder cancer	4.61e-05	0.000328	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.59e-05	0.000326	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.51e-05	0.00032	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL2—urinary bladder cancer	4.49e-05	0.000319	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.49e-05	0.000319	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—IGF1—urinary bladder cancer	4.49e-05	0.000319	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NQO1—urinary bladder cancer	4.44e-05	0.000316	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—HRAS—urinary bladder cancer	4.34e-05	0.000308	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.31e-05	0.000306	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCL8—urinary bladder cancer	4.27e-05	0.000303	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.26e-05	0.000303	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.25e-05	0.000302	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.15e-05	0.000295	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	4.14e-05	0.000294	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL2—urinary bladder cancer	4.08e-05	0.00029	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NQO1—urinary bladder cancer	4.08e-05	0.00029	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TERT—urinary bladder cancer	4.07e-05	0.000289	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.06e-05	0.000288	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.01e-05	0.000285	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	4e-05	0.000285	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—S100B—urinary bladder cancer	3.96e-05	0.000282	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NQO1—urinary bladder cancer	3.96e-05	0.000281	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.96e-05	0.000281	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.92e-05	0.000279	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.92e-05	0.000278	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.91e-05	0.000278	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—HRAS—urinary bladder cancer	3.87e-05	0.000275	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.84e-05	0.000273	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.76e-05	0.000267	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RHOA—urinary bladder cancer	3.76e-05	0.000267	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.73e-05	0.000265	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FGFR3—urinary bladder cancer	3.73e-05	0.000265	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTP1—urinary bladder cancer	3.7e-05	0.000263	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.63e-05	0.000258	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.63e-05	0.000258	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ESR1—urinary bladder cancer	3.62e-05	0.000258	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CXCL8—urinary bladder cancer	3.61e-05	0.000257	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.58e-05	0.000255	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NCOR1—urinary bladder cancer	3.56e-05	0.000253	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.56e-05	0.000253	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL2—urinary bladder cancer	3.47e-05	0.000247	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.45e-05	0.000245	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—TYMS—urinary bladder cancer	3.44e-05	0.000245	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	3.4e-05	0.000242	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NCOR1—urinary bladder cancer	3.4e-05	0.000242	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTM1—urinary bladder cancer	3.4e-05	0.000242	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.37e-05	0.00024	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.37e-05	0.00024	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.35e-05	0.000238	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.32e-05	0.000236	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTP1—urinary bladder cancer	3.3e-05	0.000235	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.3e-05	0.000234	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.29e-05	0.000234	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GPX1—urinary bladder cancer	3.26e-05	0.000232	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.25e-05	0.000231	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	3.22e-05	0.000229	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ERCC2—urinary bladder cancer	3.2e-05	0.000227	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.2e-05	0.000227	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.18e-05	0.000226	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CREBBP—urinary bladder cancer	3.18e-05	0.000226	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—TYMS—urinary bladder cancer	3.16e-05	0.000225	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL2—urinary bladder cancer	3.15e-05	0.000224	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TERT—urinary bladder cancer	3.14e-05	0.000223	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF1—urinary bladder cancer	3.14e-05	0.000223	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	3.13e-05	0.000222	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	3.13e-05	0.000222	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.12e-05	0.000222	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EGFR—urinary bladder cancer	3.12e-05	0.000222	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.08e-05	0.000219	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—TYMS—urinary bladder cancer	3.07e-05	0.000218	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NCOR1—urinary bladder cancer	3.04e-05	0.000216	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTM1—urinary bladder cancer	3.04e-05	0.000216	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.03e-05	0.000215	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—MTHFR—urinary bladder cancer	3.01e-05	0.000214	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.01e-05	0.000214	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NAT2—urinary bladder cancer	3e-05	0.000213	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GPX1—urinary bladder cancer	2.99e-05	0.000213	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—urinary bladder cancer	2.95e-05	0.00021	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	2.94e-05	0.000209	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GPX1—urinary bladder cancer	2.91e-05	0.000207	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FGFR3—urinary bladder cancer	2.88e-05	0.000205	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RHOA—urinary bladder cancer	2.87e-05	0.000204	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ERCC2—urinary bladder cancer	2.85e-05	0.000203	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.83e-05	0.000201	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ESR1—urinary bladder cancer	2.8e-05	0.000199	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.78e-05	0.000197	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	2.76e-05	0.000196	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—MTHFR—urinary bladder cancer	2.68e-05	0.000191	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.67e-05	0.00019	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ERBB2—urinary bladder cancer	2.66e-05	0.000189	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.62e-05	0.000186	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.59e-05	0.000184	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.56e-05	0.000182	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL8—urinary bladder cancer	2.52e-05	0.000179	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—urinary bladder cancer	2.51e-05	0.000178	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.45e-05	0.000174	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.44e-05	0.000173	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PPARG—urinary bladder cancer	2.44e-05	0.000173	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF1—urinary bladder cancer	2.42e-05	0.000172	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—urinary bladder cancer	2.41e-05	0.000171	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.41e-05	0.000171	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.4e-05	0.00017	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.4e-05	0.00017	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—urinary bladder cancer	2.35e-05	0.000167	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CREBBP—urinary bladder cancer	2.34e-05	0.000166	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.33e-05	0.000165	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—urinary bladder cancer	2.28e-05	0.000162	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.28e-05	0.000162	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.27e-05	0.000162	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—urinary bladder cancer	2.27e-05	0.000161	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.26e-05	0.000161	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.26e-05	0.000161	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PPARG—urinary bladder cancer	2.24e-05	0.000159	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RHOA—urinary bladder cancer	2.22e-05	0.000158	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.19e-05	0.000156	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.18e-05	0.000155	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PPARG—urinary bladder cancer	2.18e-05	0.000155	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EP300—urinary bladder cancer	2.16e-05	0.000154	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	2.15e-05	0.000153	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SRC—urinary bladder cancer	2.1e-05	0.00015	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CREBBP—urinary bladder cancer	2.09e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—urinary bladder cancer	2.05e-05	0.000146	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.04e-05	0.000145	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.95e-05	0.000138	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.93e-05	0.000138	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.93e-05	0.000137	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—urinary bladder cancer	1.92e-05	0.000136	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—urinary bladder cancer	1.88e-05	0.000134	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—urinary bladder cancer	1.86e-05	0.000132	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.85e-05	0.000131	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—urinary bladder cancer	1.84e-05	0.000131	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.82e-05	0.000129	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.76e-05	0.000125	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.75e-05	0.000124	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—urinary bladder cancer	1.74e-05	0.000124	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—urinary bladder cancer	1.71e-05	0.000122	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EP300—urinary bladder cancer	1.67e-05	0.000119	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SRC—urinary bladder cancer	1.62e-05	0.000115	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.61e-05	0.000115	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—EP300—urinary bladder cancer	1.6e-05	0.000113	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.59e-05	0.000113	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—urinary bladder cancer	1.55e-05	0.00011	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—urinary bladder cancer	1.54e-05	0.000109	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000106	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—urinary bladder cancer	1.49e-05	0.000106	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—EP300—urinary bladder cancer	1.47e-05	0.000104	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—urinary bladder cancer	1.46e-05	0.000103	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.43e-05	0.000102	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—EP300—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.41e-05	0.0001	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.39e-05	9.9e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—urinary bladder cancer	1.34e-05	9.56e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.34e-05	9.5e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.31e-05	9.33e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	9.3e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.23e-05	8.77e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—urinary bladder cancer	1.2e-05	8.5e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.19e-05	8.46e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.14e-05	8.12e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.06e-05	7.54e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	7.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1e-05	7.11e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.93e-06	7.06e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	9.61e-06	6.83e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	9.23e-06	6.56e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	9.12e-06	6.49e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	9.12e-06	6.49e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.74e-06	6.21e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.58e-06	6.1e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.35e-06	5.93e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.06e-06	5.73e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.87e-06	5.59e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.28e-06	5.18e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—EP300—urinary bladder cancer	6.94e-06	4.94e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.86e-06	4.88e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—EP300—urinary bladder cancer	6.54e-06	4.65e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.54e-06	4.65e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.28e-06	4.46e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.14e-06	3.66e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.49e-06	3.19e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.28e-06	3.04e-05	CbGpPWpGaD
